Augmentin Plus Doxycycline for Facial Cellulitis with MRSA Concern
For facial cellulitis with concern for MRSA, the combination of amoxicillin-clavulanate (Augmentin) plus doxycycline is an appropriate and guideline-supported empirical regimen that provides dual coverage for both β-hemolytic streptococci and community-acquired MRSA.
Treatment Algorithm Based on Cellulitis Type
Determining Purulent vs. Nonpurulent Status
First, classify the facial cellulitis:
- Purulent cellulitis: Presence of purulent drainage or exudate without a drainable abscess
- Nonpurulent cellulitis: No purulent drainage, exudate, or associated abscess
For Purulent Facial Cellulitis
Empirical MRSA coverage is recommended pending culture results 1. The combination of Augmentin plus doxycycline is explicitly endorsed by IDSA guidelines:
- Doxycycline 100 mg PO twice daily (provides MRSA coverage) 1
- Plus amoxicillin-clavulanate (provides streptococcal coverage) 1
- Duration: 5-10 days, individualized based on clinical response 1
This combination is specifically listed as a guideline-recommended option when coverage for both β-hemolytic streptococci and CA-MRSA is desired 1.
For Nonpurulent Facial Cellulitis
The approach depends on clinical severity:
- Initial therapy: β-lactam alone (e.g., amoxicillin-clavulanate or cephalexin) targeting streptococci 1
- Add MRSA coverage (doxycycline) if:
Important caveat: Most nonpurulent cellulitis is caused by streptococci, not MRSA, regardless of community MRSA prevalence 2. Empirical MRSA coverage may not be necessary initially 3, 2.
Special Considerations for Facial Location
Facial cellulitis warrants particular attention because:
- Facial abscesses are difficult to drain completely and require antibiotic therapy even after incision and drainage 1
- The face represents an "area difficult to drain" where antibiotics are specifically recommended 1
- Facial location increases risk of complications
Dosing Specifics
Adults:
Pediatric (≥8 years):
- Doxycycline: 2 mg/kg/dose PO every 12 hours (for children <45 kg) 1
- Amoxicillin-clavulanate: 25 mg/kg/day (amoxicillin component) in 2 divided doses 4
Critical warning: Tetracyclines (including doxycycline) should not be used in children <8 years of age 1.
Evidence Quality and Strength
The IDSA guidelines provide strong support (A-II level evidence) for this combination regimen 1. The recommendation to combine TMP-SMX or a tetracycline with a β-lactam (such as amoxicillin) for dual coverage is explicitly stated with A-II evidence grade 1.
Common Pitfalls to Avoid
Don't assume bilateral facial cellulitis is infectious - bilateral cellulitis is rare and suggests alternative diagnoses like venous stasis dermatitis 5
Don't use Augmentin alone for purulent cellulitis - it lacks reliable MRSA coverage. Augmentin is not indicated for MRSA despite some experimental data 6. The FDA label specifically states that methicillin-resistant staphylococci must be considered resistant to amoxicillin-clavulanate 7
Don't use doxycycline alone - it has poor activity against β-hemolytic streptococci 1, which remain important pathogens in facial cellulitis
Avoid overuse in nonpurulent cases - recent evidence suggests doxycycline may be reasonable for nonpurulent cellulitis 8, but β-lactam monotherapy is typically sufficient initially 3, 2
Alternative Regimens
If the combination is not suitable:
- Clindamycin alone (300-450 mg PO three times daily) provides coverage for both streptococci and MRSA 1, though C. difficile risk is higher
- Linezolid alone (600 mg PO twice daily) covers both pathogens but is significantly more expensive 1
- TMP-SMX plus amoxicillin is an alternative to doxycycline plus Augmentin 1
The Augmentin-doxycycline combination represents a cost-effective, guideline-endorsed approach that provides comprehensive coverage for facial cellulitis when MRSA is a concern, particularly in purulent cases or when initial β-lactam therapy has failed.